vaccinia virus

Summary

Summary: The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against smallpox. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.

Top Publications

  1. ncbi The interferon system and vaccinia virus evasion mechanisms
    Beatriz Perdiguero
    Department of Cellular and Molecular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, Madrid, Spain
    J Interferon Cytokine Res 29:581-98. 2009
  2. pmc Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
    Infect Immun 78:145-53. 2010
  3. pmc Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 7:e31208. 2012
  4. pmc Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry
    Jason Mercer
    Eidgenossische Technische Hochschule Zurich, Institute of Biochemistry, Eidgenössische Technische Hochschule Hoenggerberg, 8093 Zurich, Switzerland
    Proc Natl Acad Sci U S A 107:9346-51. 2010
  5. pmc Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
    Tamara K Berthoud
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    Clin Infect Dis 52:1-7. 2011
  6. pmc Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome
    Julie Delaloye
    Department of Medicine, Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    PLoS Pathog 5:e1000480. 2009
  7. pmc Repulsion of superinfecting virions: a mechanism for rapid virus spread
    Virginie Doceul
    Department of Virology, Faculty of Medicine, Imperial College London, St Mary s Campus, Norfolk Place, London W2 1PG, UK
    Science 327:873-6. 2010
  8. ncbi Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
    Simon J Draper
    Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
    J Immunol 185:7583-95. 2010
  9. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
  10. pmc Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement
    Mohammed Rafii El Idrissi Benhnia
    Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    J Virol 83:1201-15. 2009

Detail Information

Publications339 found, 100 shown here

  1. ncbi The interferon system and vaccinia virus evasion mechanisms
    Beatriz Perdiguero
    Department of Cellular and Molecular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, Madrid, Spain
    J Interferon Cytokine Res 29:581-98. 2009
    b>Vaccinia virus (VACV), a prototype member of the poxvirus family, has been used from the early times after interferons (IFN) were discovered, as a model virus cell system to analyze the mode of action of IFN...
  2. pmc Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
    Infect Immun 78:145-53. 2010
    ..TRAP). Here, we report that prime-boost regimens using modified vaccinia virus Ankara (MVA) and adenoviral vectors encoding ME...
  3. pmc Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 7:e31208. 2012
    ..falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question...
  4. pmc Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry
    Jason Mercer
    Eidgenossische Technische Hochschule Zurich, Institute of Biochemistry, Eidgenössische Technische Hochschule Hoenggerberg, 8093 Zurich, Switzerland
    Proc Natl Acad Sci U S A 107:9346-51. 2010
    To enter host cells, vaccinia virus, a prototype poxvirus, can induce transient macropinocytosis followed by endocytic internalization and penetration through the limiting membrane of pinosomes by membrane fusion...
  5. pmc Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
    Tamara K Berthoud
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    Clin Infect Dis 52:1-7. 2011
    ..A vaccine providing protective immunity to the highly conserved internal antigens could provide longer-lasting protection against multiple influenza subtypes...
  6. pmc Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome
    Julie Delaloye
    Department of Medicine, Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    PLoS Pathog 5:e1000480. 2009
    Modified vaccinia virus Ankara (MVA) is an attenuated double-stranded DNA poxvirus currently developed as a vaccine vector against HIV/AIDS...
  7. pmc Repulsion of superinfecting virions: a mechanism for rapid virus spread
    Virginie Doceul
    Department of Virology, Faculty of Medicine, Imperial College London, St Mary s Campus, Norfolk Place, London W2 1PG, UK
    Science 327:873-6. 2010
    ..Here, we show that vaccinia virus spreads across one cell every 75 minutes, fourfold faster than its replication cycle would permit...
  8. ncbi Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
    Simon J Draper
    Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
    J Immunol 185:7583-95. 2010
    ..1 in rhesus macaques (Macaca mulatta), including the chimpanzee adenovirus 63 (AdCh63), the poxvirus modified vaccinia virus Ankara (MVA), and protein vaccines formulated in Alhydrogel or CoVaccine HT adjuvants...
  9. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
    ..Prime-boost vaccination regimes involving plasmid DNA and recombinant modified vaccinia virus Ankara-encoding liver-stage malaria antigens have been shown to be powerfully immunogenic for T cells and ..
  10. pmc Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement
    Mohammed Rafii El Idrissi Benhnia
    Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    J Virol 83:1201-15. 2009
    Antibody neutralization is an important component of protective immunity against vaccinia virus (VACV)...
  11. ncbi MVA and NYVAC as vaccines against emergent infectious diseases and cancer
    Carmen E Gomez
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, Madrid, Spain
    Curr Gene Ther 11:189-217. 2011
    ..immune responses, two of the most promising poxvirus vectors for human use are the attenuated modified vaccinia virus Ankara (MVA) and the Copenhagen derived NYVAC strains...
  12. ncbi Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
    Byeong Ho Park
    Dong A University College of Medicine, Busan, South Korea
    Lancet Oncol 9:533-42. 2008
    ..We aimed to assess intratumoral injection of JX-594 in patients with refractory primary or metastatic liver cancer...
  13. ncbi Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
    Stefania Capone
    Okairos, via dei Castelli Romani 22, 00040 Pomezia, Rome, Italy
    Vaccine 29:256-65. 2010
    ..These results in non-human primates highlight the potential of this vaccination regime and encourage its future use in clinical trials...
  14. pmc Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice
    James F Papin
    International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
    Proc Natl Acad Sci U S A 108:14926-31. 2011
    ..To address this issue, we developed two recombinant RVFV vaccines using vaccinia virus (VACV) as a vector for use in livestock...
  15. ncbi Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
    Qian Zhang
    Genelux Corporation, San Diego Science Center, San Diego, California 92109, USA
    Cancer Res 67:10038-46. 2007
    Previously, we reported that a recombinant vaccinia virus (VACV) carrying a light-emitting fusion gene enters, replicates in, and reveals the locations of tumors in mice...
  16. pmc Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68
    Ivaylo Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, California, United States of America
    PLoS ONE 6:e22069. 2011
    Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy...
  17. pmc Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
    Barbara J Flynn
    Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 108:7131-6. 2011
    ..To determine whether adaptive responses could be further enhanced, animals were boosted with New York vaccinia virus (NYVAC)-HIV Gag/Pol/Nef...
  18. pmc Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations
    Natalie E R Beveridge
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:3089-100. 2007
    ..Published data have shown prime-boost vaccination with BCG-MVA85A (modified vaccinia virus Ankara expressing antigen 85A) to be highly immunogenic in humans as measured by ex vivo IFN-gamma ELISPOT...
  19. pmc Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation
    Martina Schröder
    Viral Immune Evasion Group, School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
    EMBO J 27:2147-57. 2008
    ..b>Vaccinia virus (VACV) encodes proteins that manipulate host signalling, sometimes by targeting uncharacterised proteins...
  20. pmc Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
    Dana Haddad
    Department of Biochemistry, University of Wuerzburg, Wuerzburg D 97074, Germany
    J Transl Med 9:36. 2011
    ..This study aimed to determine if insertion of the human sodium iodide symporter (hNIS) cDNA as a marker for non-invasive imaging of virotherapy alters the replication and oncolytic capability of a novel vaccinia virus, GLV-1h153.
  21. ncbi Cutting edge: long-term B cell memory in humans after smallpox vaccination
    Shane Crotty
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Immunol 171:4969-73. 2003
    ..Additionally, virus-specific CD4(+) T cells were detected decades after vaccination. These data show that immunological memory to DryVax vaccine is long-lived and may contribute to protection against smallpox...
  22. ncbi Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells
    Jason Mercer
    ETH Zurich, Institute of Biochemistry, Schafmattstrasse 18, ETH Hönggerberg HPM E6 3 Zurich, Switzerland
    Science 320:531-5. 2008
    Viruses employ many different strategies to enter host cells. Vaccinia virus, a prototype poxvirus, enters cells in a pH-dependent fashion...
  23. ncbi Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
    David H Kirn
    Jennerex Biotherapeutics Inc, San Francisco, California 94105, USA
    Nat Rev Cancer 9:64-71. 2009
    ..Initial preclinical and clinical results show that products from this therapeutic class can systemically target cancers in a highly selective and potent fashion using a multi-pronged mechanism of action...
  24. ncbi The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK
    Esther Tapia
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Campus Universidad Autonoma, 28049 Madrid, Spain
    Microbes Infect 5:73-84. 2003
    Protocols of immunization based on the DNA prime/vaccinia virus (VV) boost regime with recombinants expressing relevant antigens have been shown to elicit protection against a variety of pathogens in animal model systems, and various ..
  25. pmc A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses
    Juan García-Arriaza
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas CSIC, Madrid, Spain
    PLoS ONE 6:e24244. 2011
    The vaccinia virus (VACV) C6 protein has sequence similarities with the poxvirus family Pox_A46, involved in regulation of host immune responses, but its role is unknown...
  26. ncbi Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
    Felipe Garcia
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Vaccine 29:8309-16. 2011
    To investigate the safety and immunogenicity of a modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B), a phase-I, doubled-blind placebo-controlled trial was performed.
  27. pmc Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides
    Zhenping Wang
    Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    J Immunol 188:345-57. 2012
    ..In this study, we demonstrate that MCs react to vaccinia virus (VV) and degranulate using a membrane-activated pathway that leads to antimicrobial peptide discharge and ..
  28. pmc The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens
    Carmen Elena Gómez
    Centro Nacional de Biotecnologia, CSIC, Madrid 28049, Spain
    J Virol 85:11468-78. 2011
    ..Thus, on the basis of the immune profile of MVA-B in humans, this immunogen can be considered a promising HIV/AIDS vaccine candidate...
  29. pmc Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex
    Suany Ojeda
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0445, USA
    J Virol 80:9822-30. 2006
    The vaccinia virus G9R gene (VACWR087) encodes a protein of 340 amino acids with the following structural features that are conserved in all poxviruses: a site for N-terminal myristoylation, 14 cysteines, and a C-terminal transmembrane ..
  30. pmc Oncolytic vaccinia therapy of squamous cell carcinoma
    Zhenkun Yu
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mol Cancer 8:45. 2009
    ..Historically, vaccinia virus was administered widely to humans as a vaccine and led to the eradication of smallpox...
  31. pmc Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA
    C M Seubert
    Department of Biochemistry, University of Wurzburg, Germany
    Cancer Gene Ther 18:42-52. 2011
    ..Here, the lacZ-carrying vaccinia virus (VACV) strain GLV-1h68 was used in combination with a β-galactosidase-activatable prodrug derived from a seco-..
  32. ncbi Vaccinia virus immune evasion
    G L Smith
    Sir William Dunn School of Pathology, University of Oxford, UK
    Immunol Rev 159:137-54. 1997
    b>Vaccinia virus and other poxviruses express a wide variety of proteins which are non-essential for virus replication in culture but help the virus to evade the host response to infection...
  33. pmc Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing
    Zhilong Yang
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    Proc Natl Acad Sci U S A 107:11513-8. 2010
    Deep RNA sequencing was used to simultaneously analyze vaccinia virus (VACV) and HeLa cell transcriptomes at progressive times following infection...
  34. pmc Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate
    Jeffrey R Currier
    United States Military HIV Research Program, Rockville, Maryland, United States of America
    PLoS ONE 5:e13983. 2010
    ..The HIV sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand...
  35. pmc Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
    José Luis Nájera
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, Madrid, Spain
    PLoS ONE 5:e11406. 2010
    The highly attenuated vaccinia virus strain NYVAC expressing HIV-1 components has been evaluated as a vaccine candidate in preclinical and clinical trials with encouraging results...
  36. pmc A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics
    Theresa S Moser
    Department of Microbiology, Penn Genome Frontiers Institute, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS Pathog 6:e1000954. 2010
    ..Therefore, AMPK plays a highly conserved role in poxvirus infection and actin dynamics independent of its role as an energy regulator...
  37. pmc Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC
    Susana Guerra
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas, Campus Universidad Autonoma, E 28049 Madrid, Spain
    J Virol 81:8707-21. 2007
    ....
  38. ncbi Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
    I Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    Cancer Gene Ther 16:320-8. 2009
    ..In this study, we analyzed the functionality of the oncolytic vaccinia virus strain GLV-1h68 as a possible therapeutic agent for canine mammary cancer...
  39. ncbi Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK
    Vaccine 20:1039-45. 2002
    ..Boosting of an adenovirus-primed immune response with the replication-impaired poxvirus, modified vaccinia virus Ankara (MVA) led to enhanced immunogenicity and substantial protective efficacy...
  40. pmc Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles
    Ana Paula V Castro
    Laboratório de Biologia Molecular de Vírus, Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941 590, Brazil
    J Virol 77:9052-68. 2003
    ..the expression pattern and intracellular distribution of the cellular isomerase cyclophilin A (CypA) during vaccinia virus (VV) infection...
  41. ncbi Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
    J Schneider
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Nat Med 4:397-402. 1998
    ..consisting of single dose priming with plasmid DNA followed by a single boost with a recombinant modified vaccinia virus Ankara (MVA) expressing the same antigen, induced unprecedented complete protection against P...
  42. pmc Expression profiling of the intermediate and late stages of poxvirus replication
    Zhilong Yang
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    J Virol 85:9899-908. 2011
    The double-stranded DNA genome of vaccinia virus (VACV), the prototype poxvirus, contains approximately 200 open reading frames (ORFs) that are transcribed at early, intermediate, and late stages of infection...
  43. ncbi Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara
    Eric Sandstrom
    Department of Clinical Science and Education, Sodersjukhuset, Sweden
    J Infect Dis 198:1482-90. 2008
    ..This clinical trial evaluated the safety and immunogenicity of an HIV vaccine that combines a plasmid-DNA priming vaccine and a modified vaccinia virus Ankara (MVA) boosting vaccine.
  44. ncbi Prevention of vertical transmission of Neospora caninum in BALB/c mice by recombinant vaccinia virus carrying NcSRS2 gene
    Y Nishikawa
    The National Research Center for Protozoan Diseases, Obihiro University, Nishi 2-11, Inadacho, Obihiro, 080-8555, Hokkaido, Japan
    Vaccine 19:1710-6. 2001
    ..caninum. In conclusion, it is expected that vv/Nc-p43 can be used as an effective live vaccine to prevent vertical transmission of N. caninum in natural hosts...
  45. pmc Analysis of A47, an immunoprevalent protein of vaccinia virus, leads to a reevaluation of the total antiviral CD8+ T cell response
    Tracy J Yuen
    Division of Biomedical Science and Biochemistry, Research School of Biology, College of Medicine, Biology and the Environment, The Australian National University, Canberra, ACT, Australia
    J Virol 84:10220-9. 2010
    b>Vaccinia virus (VACV) is the prototypic orthopoxvirus and was the live vaccine used to eradicate smallpox. In addition, VACV is a possible vector for recombinant vaccines...
  46. pmc Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy
    Alexa Frentzen
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    Proc Natl Acad Sci U S A 106:12915-20. 2009
    We previously reported that the replication-competent vaccinia virus (VACV) GLV-1h68 shows remarkable oncolytic activity and efficacy in different animal models as a single treatment modality and also in combination with chemotherapy [Yu ..
  47. pmc Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions
    Christiana Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10230-7. 2004
    Infectious intracellular and extracellular forms of vaccinia virus have different outer membrane proteins, presenting multiple targets to the immune system...
  48. ncbi Poxvirus vector-based HIV vaccines
    Giuseppe Pantaleo
    Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
    Curr Opin HIV AIDS 5:391-6. 2010
    ....
  49. pmc Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, AL 35294, USA
    J Infect Dis 203:610-9. 2011
    Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine...
  50. pmc The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
    Qian Zhang
    Genelux Corporation, San Diego Science Center, 3030 Bunker Hill St, Ste 310, San Diego, CA 92109, USA
    Mol Genet Genomics 282:417-35. 2009
    As a new anticancer treatment option, vaccinia virus (VACV) has shown remarkable antitumor activities (oncolysis) in preclinical studies, but potential infection of other organs remains a safety concern...
  51. pmc Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination
    Wolfgang Kastenmuller
    Institute of Molecular Virology, Antigen specific Immunotherapy Clinical Cooperation Group, National Research Center for Environment and Health, 81675 Munich, Germany
    J Exp Med 204:2187-98. 2007
    ..In our study using a vaccinia virus infection model, we found that T cell cross-competition is highly relevant during boost vaccination, thereby ..
  52. pmc Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68
    Ivaylo Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    J Biomed Biotechnol 2010:489759. 2010
    Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy...
  53. pmc Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence
    Aodhnait S Fahy
    Department of Virology, Faculty of Medicine, Imperial College London, St Mary s Campus, Norfolk Place, London W2 1PG, UK
    J Gen Virol 89:2377-87. 2008
    The vaccinia virus (VACV) strain Western Reserve C16 protein has been characterized and its effects on virus replication and virulence have been determined...
  54. pmc Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)
    Matthew G Cottingham
    Wellcome Trust Centre for Human Genetics and The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1638. 2008
    The production, manipulation and rescue of a bacterial artificial chromosome clone of Vaccinia virus (VAC-BAC) in order to expedite construction of expression vectors and mutagenesis of the genome has been described (Domi & Moss, 2002,..
  55. pmc Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68
    Yong A Yu
    Genelux Corporation, San Diego Science Center, 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109, USA
    Mol Cancer Ther 8:141-51. 2009
    ..Here, we investigated the therapeutic efficacy of a replication-competent vaccinia virus, GLV-1h68, against human pancreatic carcinomas in cell cultures and in nude mice...
  56. ncbi Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
    Muhammad Bakari
    Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Vaccine 29:8417-28. 2011
    ....
  57. pmc Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma
    Ivaylo Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, California, United States of America
    PLoS ONE 7:e37239. 2012
    Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy...
  58. pmc Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype
    Norman Yeh
    Department of Microbiology and Immunology, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Immunol 185:2089-98. 2010
    ..In this study, we explored the anti-viral activity of Tc17 cells using a vaccinia virus (VV) infection model...
  59. pmc Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence
    Carlos Maluquer de Motes
    Department of Virology, Faculty of Medicine, Imperial College London, London, United Kingdom
    PLoS Pathog 7:e1002430. 2011
    b>Vaccinia virus (VACV) protein N1 is an intracellular virulence factor and belongs to a family of VACV B-cell lymphoma (Bcl)-2-like proteins whose members inhibit apoptosis or activation of pro-inflammatory transcription factors, such as ..
  60. pmc Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts
    Zhilong Yang
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    J Virol 85:5897-909. 2011
    ..Genome-wide microarray and RNA-seq technologies have been used to profile the transcriptome of vaccinia virus (VACV), the prototype member of the family...
  61. pmc Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7
    Leonie Unterholzner
    School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
    PLoS Pathog 7:e1002247. 2011
    ..Here the vaccinia virus (VACV) protein C6 is identified as an inhibitor of PRR-induced IFN-β expression by a functional screen of ..
  62. pmc Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine Treatment and Evaluation Unit, 1100 S Grand Blvd DRC 8, St Louis, MO 63104, USA
    Vaccine 25:8562-73. 2007
    ..IMVAMUNE vaccination prior to Dryvax reduced virus replication at the Dryvax site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response...
  63. pmc A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
    Michael C Keefer
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA michael
    Vaccine 29:1948-58. 2011
    ..Thus, a heterologous poxvirus vector prime-boost regimen can induce HIV-specific CD8+ T-cell and CD4+ T-cell responses, which may be an important feature of an optimal regimen for preventive HIV vaccination...
  64. ncbi Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C
    Carmen Elena Gómez
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Vaccine 25:1969-92. 2007
    Recombinants based on the attenuated vaccinia virus strains MVA and NYVAC are considered candidate vectors against different human diseases...
  65. pmc The Vaccinia virus complement control protein modulates adaptive immune responses during infection
    Natasha M Girgis
    University of Pennsylvania School of Medicine, Division of Infectious Diseases, 502 Johnson Pavilion, Philadelphia, PA 19104 6073, USA
    J Virol 85:2547-56. 2011
    ..b>Vaccinia virus (VACV) modulates complement activation by encoding a complement regulatory protein called the vaccinia virus ..
  66. ncbi Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model
    Joost H C M Kreijtz
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Gen Virol 91:2745-52. 2010
    ..Modified vaccinia virus Ankara (MVA), originally developed as a safe smallpox vaccine, can be exploited as a viral vector and has many ..
  67. pmc Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis
    Elma Z Tchilian
    The Jenner Institute, Oxford University, ORCRB, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Infect Immun 77:622-31. 2009
    ..hly(+) BCG (recBCG), which has been developed to replace the current BCG vaccine strain, and modified vaccinia virus Ankara (MVA) expressing M...
  68. pmc Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:9458-63. 2003
    ..in immunocompromised animals, was equivalent to that of the licensed Wyeth vaccine strain against a pathogenic vaccinia virus intranasal challenge of mice...
  69. pmc Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques
    Maximillian Rosario
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, United Kingdom
    J Virol 84:7815-21. 2010
    ..HIVA(401) or its parental strain AERAS-401, followed by two doses of recombinant modified vaccinia virus Ankara MVA.HIVA. The HIVA immunogen is derived from African clade A HIV-1...
  70. ncbi IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17
    Shunsuke Kohyama
    Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    J Immunol 179:3917-25. 2007
    To investigate roles of IL-23 in viral infection, we have engineered recombinant vaccinia virus (VV) expressing IL-12 (VV-IL-12) and expressing IL-23 (VV-IL-23)...
  71. ncbi Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..The three delivery vectors are DNA, modified vaccinia virus Ankara (MVA) and, more recently, fowlpox strain 9 (FP9)...
  72. pmc Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
    Christofer Samuelsson
    Department of Research, Bavarian Nordic, Martinsried, Germany
    J Clin Invest 118:1776-84. 2008
    ..In contrast, we found that the strongly attenuated poxvirus modified vaccinia virus Ankara (MVA) activated DCs by both TLR9-dependent and -independent pathways...
  73. ncbi GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases
    V E Volchkov
    State Research Centre of Virology and Biotechnology Vector, Institute of Molecular Biology, Koltsovo, Novosibirsk Region, Russia
    Virology 214:421-30. 1995
    ..Expression of the glycoprotein by an in vitro transcription/translation system, by the vaccinia virus/T7 polymerase system, and by recombinant vaccinia virus revealed that full-length glycoprotein was synthesized ..
  74. pmc Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells
    Arban Domi
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0445, USA
    Proc Natl Acad Sci U S A 99:12415-20. 2002
    The ability to manipulate the vaccinia virus (VAC) genome, as a plasmid in bacteria, would greatly facilitate genetic studies and provide a powerful alternative method of making recombinant viruses...
  75. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ..We evaluated several DNA vaccine formulations, a modified vaccinia virus Ankara vector, and a replication-defective adenovirus serotype 5 (Ad5) vector, each expressing the same codon-..
  76. pmc Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection
    Stephanie Weibel
    Department of Biochemistry, Biocenter, University of Wuerzburg, D 97074 Wuerzburg, Germany
    BMC Cancer 11:68. 2011
    ..In this study, we analyzed the contribution of these factors to elucidate the responsible mechanism for regression of human breast tumor xenografts upon colonization with an attenuated vaccinia virus (VACV).
  77. pmc Smallpox vaccines: targets of protective immunity
    Bernard Moss
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    Immunol Rev 239:8-26. 2011
    ..one of the great triumphs of medicine, was accomplished through the prophylactic administration of live vaccinia virus, a comparatively benign relative of variola virus, the causative agent of smallpox...
  78. ncbi Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara
    Caroline Staib
    GSF Institute of Molecular Virology and Institute of Virology, Technical University of Munich, Trogerstrasse 4b, 81675 Munchen, Germany
    J Gen Virol 86:1997-2006. 2005
    ..b>Vaccinia virus encodes a viral soluble IL1beta receptor (IL1betaR), which modulates the acute-phase host response to ..
  79. pmc Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus
    Koert J Stittelaar
    Department of Virology, Erasmus MC, Building Hoboken, Room Ee 17 26, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    J Virol 79:7845-51. 2005
    The use of classical smallpox vaccines based on vaccinia virus (VV) is associated with severe complications in both naive and immune individuals...
  80. ncbi Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection
    Eva Calvo-Pinilla
    Centro de Investigacion en Sanidad Animal, INIA, 28130 Valdeolmos, Madrid, Spain
    Vaccine 28:437-45. 2009
    ..new vaccination strategies against BTV infection we have engineered naked DNAs and recombinant modified vaccinia virus Ankara (rMVA) expressing VP2, VP5 and VP7 proteins from BTV-4...
  81. pmc New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1
    Anna L Goodman
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Infect Immun 78:4601-12. 2010
    ..falciparum. These vectored vaccines should allow assessment in humans of the safety and efficacy of inducing strong cellular as well as cross-strain humoral immunity to P. falciparum MSP-1...
  82. ncbi Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
    ..These viral vectors now provide a major option for inclusion in a high efficacy multi-stage malaria vaccine that should achieve deployable levels of efficacy in endemic settings...
  83. ncbi The rate of N-WASP exchange limits the extent of ARP2/3-complex-dependent actin-based motility
    Ina Weisswange
    Cell Motility Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Nature 458:87-91. 2009
    ..NCK, which are required to stimulate actin-related protein (ARP)2/3-complex-dependent actin-based motility of vaccinia virus, using fluorescence recovery after photobleaching...
  84. pmc Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve
    Carla Oseroff
    Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Immunol 180:7193-202. 2008
    Understanding immunity to vaccinia virus (VACV) is important for the development of safer vaccines for smallpox- and poxvirus-vectored recombinant vaccines...
  85. pmc A role for Z-DNA binding in vaccinia virus pathogenesis
    Yang Gyun Kim
    Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Room 68 233, Cambridge, MA 02139 4307, USA
    Proc Natl Acad Sci U S A 100:6974-9. 2003
    The N-terminal domain of the E3L protein of vaccinia virus has sequence similarity to a family of Z-DNA binding proteins of defined three-dimensional structure and it is necessary for pathogenicity in mice...
  86. pmc Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model
    Kaitlyn J Kelly
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Cancer 124:911-8. 2009
    ..We aimed to investigate the use of recombinant vaccinia virus GLV-1h68, expressing green fluorescent protein (GFP), for real-time intraoperative detection of melanoma lymph ..
  87. pmc Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
    David H Kirn
    Jennerex Biotherapeutics, San Francisco, California, United States of America
    PLoS Med 4:e353. 2007
    ..We have previously demonstrated that vaccinia virus strains are capable of systemic delivery to tumors in mouse models, but infection of normal tissues remains an ..
  88. ncbi Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7
    Shun ichiro Oda
    School of Biochemistry and Immunology, Trinity College, Dublin, Dublin 2, Ireland
    Structure 17:1528-37. 2009
    Poxviruses are DNA viruses that express numerous proteins to subvert the host immune response. Vaccinia virus protein K7 adopts a Bcl-2 fold and displays structural and functional similarities to Toll-like receptor antagonist A52...
  89. ncbi Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes
    J A McCart
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892-1502, USA
    Cancer Res 61:8751-7. 2001
    We have demonstrated previously the oncolytic effects of a systemically delivered, replicating vaccinia virus. To enhance the tumor specificity of this vector, we have developed a combined thymidine kinase-deleted (TK-) and vaccinia ..
  90. pmc Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
    Andrea Worschech
    Genelux Corporation, San Diego Science Center, San Diego, California, USA
    BMC Genomics 10:301. 2009
    GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes established human xenografts inducing their complete regression.
  91. ncbi Cellular and humoral immunity against vaccinia virus infection of mice
    Rong Xu
    Department of Immunology and Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA
    J Immunol 172:6265-71. 2004
    Despite the widespread use of vaccinia virus (VV) as a vector for other Ags and as the smallpox vaccine, there is little information available about the protective components of the immune response following VV infection...
  92. ncbi Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses
    J H C M Kreijtz
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    Vaccine 27:6296-9. 2009
    ..Modified vaccinia virus Ankara (MVA) expressing the HA gene of an influenza A/H5N1 virus is a promising candidate vaccine that induced ..
  93. pmc Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities
    Tod J Merkel
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:18091-6. 2010
    ..anthracis into the Wyeth vaccinia virus. Integration of IL-15 renders Wyeth vaccinia avirulent in immunodeficient mice and enhances anti-vaccinia ..
  94. ncbi Zoonotic vaccinia virus: clinical and immunological characteristics in a naturally infected patient
    Giliane S Trindade
    Departamento de Microbiologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
    Clin Infect Dis 48:e37-40. 2009
    b>Vaccinia virus was used as vaccine to eradicate smallpox. We report a zoonotic case of vaccinia virus infection in a 30-year-old patient who became infected after handling sick dairy cattle...
  95. pmc Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi
    Mekki Bensaci
    Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA
    Vaccine 30:6040-6. 2012
    ..efficacy of subolesin, a conserved tick protein that can act as a regulator of gene expression, expressed from vaccinia virus for use as an orally delivered reservoir - targeted vaccine for prevention of tick infestation and acquisition/..
  96. ncbi Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1
    B Huang
    Departments of Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15238, USA
    Gene Ther 18:164-72. 2011
    ..These data may provide a direct basis for the design of clinical trials with agents currently in the clinic, as well as providing insight into the development of next generation viral vectors...
  97. pmc Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein
    Juliana Falivene
    Centro Nacional de Referencia para el SIDA, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
    PLoS ONE 7:e32220. 2012
    Modified Vaccinia Ankara (MVA) is an attenuated strain of Vaccinia virus (VACV) currently employed in many clinical trials against HIV/AIDS and other diseases...
  98. ncbi Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses
    L K Selin
    Department of Pathology, University of Massachusetts Medical School, Worcester 01655, USA
    Immunity 11:733-42. 1999
    ..These results are consistent with a model for the immune system that accommodates memory T cell populations for multiple pathogens over the course of a lifetime...
  99. pmc Vaccinia virus temperature-sensitive mutants in the A28 gene produce non-infectious virions that bind to cells but are defective in entry
    Peter C Turner
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610 0266, USA
    Virology 366:62-72. 2007
    The vaccinia virus temperature-sensitive mutations Cts6 and Cts9 were mapped by marker rescue and DNA sequencing to the A28 gene...
  100. pmc Chemokines control naive CD8+ T cell selection of optimal lymph node antigen presenting cells
    Heather D Hickman
    Cell Biology and Viral Immunology Sections, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 208:2511-24. 2011
    ..DCs rather than macrophages, we performed intravital microscopy and ex vivo analyses after infecting mice with vaccinia virus (VV), a large DNA virus that infects both LN macrophages and DCs...
  101. ncbi Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread
    Mansun Law
    Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK
    J Gen Virol 83:209-22. 2002
    The roles of vaccinia virus (VV) intracellular mature virus (IMV), intracellular enveloped virus (IEV), cell-associated enveloped virus (CEV) and extracellular enveloped virus (EEV) and their associated proteins in virus spread were ..

Research Grants74

  1. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2010
    ..the initial findings of Edward Jenner that people exposed to cowpox did not get sick from smallpox, a modified vaccinia virus was used to vaccinate against both cowpox and smallpox...
  2. Collagen X and heparan sulfate proteoglycan in the hematopoietic stem cell niche.
    ELIZABETH G SWEENEY; Fiscal Year: 2012
    ..Pennsylvania in the Department of Infectious Diseases in Medicine engineering and characterized various novel Vaccinia virus vectors to be used as live vaccine prophylactics...
  3. Programming of Protective CD8 T-Cell Memory by Live and Adjuvanted Subunit Vaccin
    Marulasiddappa Suresh; Fiscal Year: 2013
    ..response elicited by this adjuvant was as strong as those induced by infection with recombinant listeria and vaccinia virus, which are known to stimulate robust cell-mediated immunity...
  4. Development of an effective genital herpes vaccine
    William P Halford; Fiscal Year: 2010
    ..Live vaccinia virus (the original vaccine) was used to end smallpox epidemics...
  5. Immune Mechanisms That Control Ectromelia Virus Infection
    Luis J Sigal; Fiscal Year: 2013
    ..None of this is true for vaccinia virus (VACV), an orthopoxvirus of unknown origin, frequently used in mouse models of immunity, and made all the more ..
  6. Protective orthopox immunization in normals and patients with cancer or eczema
    Ellis Reinherz; Fiscal Year: 2009
    ..Project 1 will examine protective immunity to vaccinia virus in normal and high-risk patients elicited during virus vaccination trials based on parameters identified in ..
  7. Host defense against poxviruses and viral immune evasion
    Liang Deng; Fiscal Year: 2011
    ..that the cytosolic dsRNA sensing pathway mediated by MDA5/MAVS/IRF3 plays an important role in sensing vaccinia virus in epithelial cells, which is antagonized by the dsRNA binding domain of vaccinia virulence factor E3...
  8. Molecular Biology of Eukaryotic Viruses
    Bert L Semler; Fiscal Year: 2012
    ..yeast Ty3, poliovirus, human rhinovirus, coxsackievirus, mouse hepatitis virus, SARS coronavirus, arenaviruses, herpes simplex virus, Epstein-Barr virus, human papillomavirus, vaccinia virus, and a number of RNA-containing plant viruses.
  9. Encapsidation of the poxvirus genome
    Paula Traktman; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Poxviruses, such as vaccinia virus, are unique among DNA viruses in replicating solely within the cytoplasm of the infected cell...
  10. ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES
    Stanley R Riddell; Fiscal Year: 2010
    ..Aim 2. To determine if primary or booster vaccination of humans with vaccinia virus induces a longlived subset of vaccinia virus-specific CD8+ CMhi and EMhi T cells...
  11. Development of a multivalent vaccine for mouse reservoirs of deer tick pathogens
    Linden T Hu; Fiscal Year: 2010
    ..Our laboratory has been involved in developing a vaccinia virus (VV) based anti-Borrelia burgdorferi vaccine for white-footed mice based on the outer surface A (OspA) protein ..
  12. A Novel Approach for Mycobacterium Tuberculosis Vaccine Development
    Biao He; Fiscal Year: 2013
    ..Sixth, in a side-by-side comparison of PIV5 expressing HIV Gag protein (PIV5-gag) and a vaccinia virus (MVA) expressing Gag (MVA-Gag), PIV5-Gag induced better cellular immune responses than MVA-Gag in mice in our ..
  13. Programmed necrosis in Immune Responses
    Francis Ka Ming Chan; Fiscal Year: 2013
    ..Finally, we will evaluate the physiological relevance of RIP3-dependent programmed necrosis using vaccinia virus infection as a model...
  14. Therapeutic vaccination against genital HPV infection
    Yung Nien Chang; Fiscal Year: 2013
    ..TA-HPV is vaccinia virus engineered to express the E6 and E7 genes from HPV16 and HPV18...
  15. Dermatotropic cellular immune responses induced by a novel smallpox vaccine
    Stephen R Walsh; Fiscal Year: 2013
    ..We hypothesize that the epicutaneous inoculation and subsequent intradermal (ID) replication of wild-type vaccinia virus (VACV) leads to preferential selection of poxvirus-specific T cells which express skin-tropic lymphocyte ..
  16. Oncolytic Viruses with Therapeutic Genes in the Treatment of Breast Cancer
    DANUTA B KOZBOR; Fiscal Year: 2013
    ..Furthermore, our preliminary results demonstrated that oncolytic vaccinia virus (OVV) expressing an antagonist of the CXCR4 receptor for CXCL12 chemokine (OVV- CXCR4-A-Fc) was more effective ..
  17. Skin Homing T Cells -- Molecular Characterization of CLA
    Thomas S Kupper; Fiscal Year: 2012
    ..fully define the immunophysiology of these phenomena, we have used murine models of cutaneous infection with vaccinia virus to track a T cell mediated, antigen-specific immune response from draining lymph node and subsequently to both ..
  18. Vaccinia Virus Genetics and Morphogenesis
    Richard C Condit; Fiscal Year: 2013
    ....
  19. Virulence Mechanisms of Viral Bcl-2 Homologs
    Shu Ichi Matsuzawa; Fiscal Year: 2013
    ..In Vaccinia Virus (VV), a poxvirus-family member that has served as a paradigm for investigations of many aspects of host-..
  20. Study of gamma interferon agonists/mimetics
    Howard M Johnson; Fiscal Year: 2012
    ..1. Protection of mice against lethal vaccinia virus infections by IFN mimetics. Effect of SOCS-1 antagonist on protection. 2...
  21. Small Molecule Inhibitors of the Poxvirus Type I Interferon Binding Protein
    Luis J Sigal; Fiscal Year: 2013
    ..variola virus (VARV), the zoonotic viruses monkeypox (MPXV) and cowpox virus (CPXV)~ the vaccine species vaccinia virus (VAC) which is also responsible for zoonoses in Brazil and India, and the mouse pathogen Ectromelia virus (..
  22. INTERFERON ACTION AND PROTEIN PHOSPHORYLATION
    Charles E Samuel; Fiscal Year: 2013
    ..human cell clones will be examined for the mechanisms by which PKR affects virus replication, with emphasis on vaccinia virus (wild-type and E3L mutant), and measles virus (wild- type, V and C mutants) and adenovirus (VAI mutant), ..
  23. Mechanisms of humoral immunity development and function to the smallpox vaccine
    SHANE P CROTTY; Fiscal Year: 2013
    ..Vaccines are one of the most cost-effective medical treatments in modern civilization. The smallpox vaccine (vaccinia virus, VACV) has been extraordinarily effective, having brought about the worldwide eradication of smallpox disease...
  24. Novel Strategies for Cancer Immunotherapy in Stem Cell Transplant
    Yiping Yang; Fiscal Year: 2013
    ..We have also discovered that vaccinia virus (VV)-based vaccines can even more potently activate tumor-specific CD8 T cell response post-transplant due to ..
  25. Therapeutics that target processivity complex proteins of pox and other viruses
    ROBERT PAUL RICCIARDI; Fiscal Year: 2013
    ..We have now established that processive DMA synthesis of vaccinia virus (W) requires three proteins, an E9 DMA polymerase and the A20, D4R processivity factors...
  26. Clinical Development of Combination Plague/Smallpox Vaccine
    CHARALAMBOS PARTIDOS; Fiscal Year: 2011
    ..pestis antigens in the poxvirus vector, modified vaccinia virus Ankara (MVA) and evaluated the efficacy and safety profile of several recombinant MVA-based plague vaccines...
  27. VACCINIA DNA REPLICATION
    Paula Traktman; Fiscal Year: 2013
    ..In this proposal, we present our plan for continued investigation of how vaccinia virus, the prototypic poxvirus, accomplishes genome replication...
  28. Evasion of antiviral protection by poxvirus-encoded interferon antagonists
    Sergei V Kotenko; Fiscal Year: 2010
    ..protein from Yaba-like disease virus, a yatapoxvirus, is a secreted glycoprotein related to protein B18 from Vaccinia virus, a known type I IFN binding protein and a member of the immunoglobulin superfamily...
  29. Mechanisms of vaccinia virus dissemination
    HERVE F AGAISSE; Fiscal Year: 2013
    ..both the causative agent of smallpox, variola virus, and the vaccine strain used for smallpox eradication, Vaccinia virus. Even though naturally occurring smallpox has been successfully eradicated, we need to better understand the ..
  30. VACCINIA VIRUS BIOCHEMICAL GENETICS
    Richard C Condit; Fiscal Year: 2013
    ..the molecular mechanisms governing post-initiation events in postreplicative gene transcription during vaccinia virus infection...
  31. BCG as an HIV vaccine vector
    Anna Lise Williamson; Fiscal Year: 2011
    ..of rBCG expressing HIV genes in combination with matched virus like particles (VLP) and modified vaccinia virus Ankara (MVA) based HIV candidate vaccines initially in mice and then in non-human primates...
  32. SLAT: A novel GEF coordinating actin remodeling and Ca2+ signaling in T cells
    Amnon Altman; Fiscal Year: 2013
    ..T cell activation and expansion to study whether SLAT is required for pathogen (Listeria Monocytogenes and Vaccinia virus) clearance, and whether the Ca2+ signaling defect is the cause of impaired CD8+ T cell responses observed in ..
  33. Poxvirus Modulation of Immune Responses
    Janice S Blum; Fiscal Year: 2010
    ..b>Vaccinia virus has been widely used as an infectious vaccine agent to induce immunity against smallpox...
  34. Development of a therapy for Smallpox, Vaccinia, and Monkeypox
    Alexander Rich; Fiscal Year: 2010
    ..b>Vaccinia virus, when injected into a mouse, is lethal in slightly more than a week...
  35. Skin Homing T Cells
    Thomas S Kupper; Fiscal Year: 2013
    ..our vantage point, we will use three distinct models of skin immune responses: contact hypersensitivity (CHS), vaccinia virus (VACV) infection, and C...
  36. Characterization of the Molecular Mechanism of MVA-induced NF-kappaB Activation
    Stefani Martin; Fiscal Year: 2012
    NF-?B is a conserved eukaryotic transcription factor that controls proinflammatory and immune genes. Vaccinia virus (VV) inhibits NF-?B activation through a number of viral immunevasion proteins...
  37. Poxvirus interface with skin immune system, development of anti-poxvirus drugs
    Liang Deng; Fiscal Year: 2010
    ..The specific aims of the proposal are to (i) Use genetically modified vaccinia virus to dissect how vaccinia virus intersects TLR signaling, and the NF-?B and IFN pathways in LCs/DCs;Determine ..
  38. Improving Vaccinia for Peritoneal Tumors: Enhanced Distribution &Immune Evasion
    David L Bartlett; Fiscal Year: 2013
    ..poxviruses for oncolytic viral therapy, and we previously developed a tumor-selective, replicating oncolytic vaccinia virus for clinical use (vvDD)...
  39. VIRUS INDUCED IMMUNOPATHOLOGY
    Raymond M Welsh; Fiscal Year: 2013
    ..models to contribute to either enhanced or reduced viral loads and remarkably altered immunopathology against vaccinia virus, arenaviruses, influenza virus, and cytomegalovirus...
  40. IN-SITU ACTIVATION OF ANTITUMOR EFFECTORS
    Edmund C Lattime; Fiscal Year: 2012
    ..lymph node / and systemic immunity axis as a means of further identifying targets for manipulation using vaccinia virus recombinants: "The tumor microenvironment as a "factory" for systemic unresponsiveness";2...
  41. The Role of Leukocyte Sequestration in the Control of Viral Infections
    John Altman; Fiscal Year: 2009
    ..we will turn to four well established mouse models of viral infection: lethal intranasal infection with vaccinia virus, lethal intranasal infection with influenza virus, infection of newborn tumor-susceptible mice with polyoma ..
  42. Pathways fo Lambda Site-Specific Recombination
    ANCA MARA SEGALL; Fiscal Year: 2010
    ..of catalysis to cut and rejoin DNA strands as the structurally homologous type IB topoisomerases, of which the vaccinia virus topoisomerase and human topoisomerase I are the best studied examples...
  43. Smallpox vaccine and vaccinia complement control protein
    STUART ISAACS; Fiscal Year: 2009
    ..Define the in vitro replication and in vivo pathogenicity of vaccinia virus mutants in which we selectively modify the VCP gene to manipulate its function. 2...
  44. LTQ Velos Pro mass spectrometer with ETD and other options
    Paul D Gershon; Fiscal Year: 2013
    ..investigation of the molecular mechanisms underlying the modulation of cell signaling upon infection by vaccinia virus (Dr. Gershon);global cellular responses to polio and rhinovirus (Dr. Semler) and Chlamydia infection (Dr...
  45. Pathways of Antigen Presentation to CD8 T Cells In Vivo
    Christopher C Norbury; Fiscal Year: 2013
    ..In Aim 1 we will explore the mechanisms responsible for a novel mode of immune evasion in which late vaccinia virus antigens are prevented from entering the cross presentation pathway...
  46. Functional genomic analysis of the CD8 T cell response to HIV vaccines in
    MARGARET JULIANA MCELRATH; Fiscal Year: 2013
    ..We will compare these HIV-specific CD8 profiles to antigen-specific CD8 T cells responding to vaccines against vaccinia virus (VV) - one of the most successful vaccines ever developed...
  47. Immune modulation mechanism mediated by poxvirus IL-18 binding protein
    Yan Xiang; Fiscal Year: 2011
    ..18) inhibitor that is secreted by a wide variety of poxviruses, including variola virus, monkeypox virus and vaccinia virus. IL-18 is a pleiotropic cytokine that enhances both the innate and acquired immunity [1, 2]...
  48. Identifying the role of 4-1BB in generation and persistence of VACV-CD8 memory
    Yuan Zhao; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Vaccinia virus (VACV) affords long-lasting protection against variola virus, the agent of smallpox...
  49. Pathogenesis of Vaccinia virus keratitis
    Curtis R Brandt; Fiscal Year: 2013
    ..ER personnel) and the military. The Smallpox vaccine, Vaccinia virus, is a live attenuated virus and adverse vaccine responses are common...
  50. Delivery system development for a reservoir targeted Lyme disease vaccine
    Linden T Hu; Fiscal Year: 2013
    ..Linden Hu at Tufts University. Dr. Hu's laboratory has developed an oral vaccine for mice using a vaccinia virus vector expressing the B. burgdorferi protein outer surface protein A (OspA)...
  51. Mechanisms for NK Cell Activation in Vaccinia Virus Control
    Yiping Yang; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Vaccinia virus (VV) is the live smallpox vaccine responsible for the successful eradication of smallpox worldwide...
  52. Enhancing Delivery and Regulating Gene Expression in Oncolytic Vaccinia Vectors
    Stephen H Thorne; Fiscal Year: 2013
    ..provided by applicant): We have previously designed and implemented a variety of oncolytic vectors based on vaccinia virus, developing a panel of gene-deleted and tumor-targeting strains that have displayed promising pre- clinical ..
  53. TNFR Members in T Cell Immunity to Vaccinia
    Michael Croft; Fiscal Year: 2012
    ..and role of several TNF/TNFR superfamily molecules in the development of the anti-viral T cell response to vaccinia virus. We propose that these molecules might be targets for improving our ability to effectively vaccinate...
  54. ST-246 treatment of smallpox vaccine-related adverse events
    Douglas W Grosenbach; Fiscal Year: 2011
    ..to us that ST-246 might also be used to prevent or treat adverse events due to the smallpox vaccine, a live vaccinia virus closely related to variola...
  55. DsRNA Characterization in Monkeypox-infected Cells
    Bertram L Jacobs; Fiscal Year: 2013
    ..The monkeypox virus homologue of the variola virus (and vaccinia virus) E3L gene, which is an important vaccinia virus innate immune evasion gene, is partially deleted...
  56. Directing Tumor-specific T cells to Tumors
    Pawel Kalinski; Fiscal Year: 2013
    ..Cells in the CMS Tumors: the Key to Efficient Anti-tumor Immunity;Project 3: Tumor-selective Oncolytic Vaccinia Virus and aDC1-based Vaccine as a Combination Therapy for Colorectal Cancer...
  57. TNFR Members in T Cell Immunity to Vaccinia
    Michael Croft; Fiscal Year: 2010
    ..4-1BB-4-1BBL will play essential non-redundant roles in directing the priming of CD8 and CD4 cells induced by vaccinia virus and for inducing long-lasting memory...
  58. MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION
    Danuta Kozbor; Fiscal Year: 2001
    ..immunization, in which a non-viral vector such as a DNA vaccine is given, followed by a viral vector such as vaccinia virus, results in robust CTL and CD4 T cell responses in mice and non-human primates...
  59. Vaccinia Proteome Affinity Reagents From Phage Display
    Philip Felgner; Fiscal Year: 2005
    ..In this project, reagents with high affinity and specificity for vaccinia virus proteins will be selected from phage-displayed libraries...
  60. Evolutionary potential of a model poxvirus
    Nels C Elde; Fiscal Year: 2013
    ..Aim 3 ofthis program entails experimental evolution of vaccinia virus in different host cell lines...
  61. Antigen Persistence and Protective Immunity After Protein Vaccination
    Ross M Kedl; Fiscal Year: 2013
    ..e. Vaccinia virus, MMR) can produce immune memory lasting for many decades without any need for boosting...
  62. Optimizing the formulation of a protein based smallpox vaccine
    Stuart N Isaacs; Fiscal Year: 2012
    ..The majority of our prior development of a protein-based smallpox vaccine has been with Vaccinia virus proteins, which based on their high homology to variola virus proteins, could confer cross protection against ..
  63. The Role of Toll-Like Receptors in Cancer Immunotherapy
    Yiping Yang; Fiscal Year: 2009
    ..following five aims: 1) To determine if reversal of TReg cell-mediated tumor-specific CDS tolerance in vivo by vaccinia virus vs...
  64. RECOMBINANT POLYTYPIC CHLAMYDIA VACCINE
    LUIS DE LA MAZA; Fiscal Year: 1991
    ..In this proposal the first step is toe construct a chimeric vaccinia virus vaccine with the gene coding for the major outer membrane protein (MOMP) of the C. trachomatis L3 serovar...
  65. NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS
    JOHN SECRIST; Fiscal Year: 2003
    ..for our study are carbocyclic 3-deazaadenosine, which has reproducible and potent in vitro and in vivo anti-vaccinia virus activities, and N1- aralkyloxyadenosines, which have reproducible and potent in vitro anti- vaccinia virus ..
  66. Choosing Drug Doses for Biodefense Pathogens
    George Drusano; Fiscal Year: 2009
    ..treat patients infected with the Bioterror pathogens Bacillus anthracis, Yersinia pestis and the Pox viruses Vaccinia Virus and Cowpox Virus...
  67. VACCINIA VIRUS VACCINE FOR TYPE 1 DIABETES
    William Langridge; Fiscal Year: 2003
    ..In response to RFA-DK-02-023, we propose to determine the feasibility of a recombinant vaccinia virus (rVV) mediated autoantigen delivery system for suppression of Type 1 diabetes...
  68. Host proteins in Vaccinia viral membrane biogenesis
    Victor Hsu; Fiscal Year: 2004
    Much interest exists in understanding the replication of vaccinia virus, as it represents the model system to understand poxviruses that include variola virus, the causative agent of smallpox...
  69. Bacterial Commensal Vector Delivery/Smallpox Vaccine
    Dennis Hruby; Fiscal Year: 2006
    ..There is an effective vaccine available (vaccinia virus), but because of a small but significant risk of serious complications (including death) associated with ..
  70. VACCINIA VIRUS LATE TRANSCRIPTION FACTOR
    Cynthia Wright; Fiscal Year: 2003
    ..Gene expression in vaccinia virus, the prototypic member of the poxvirus family, is temporally regulated and can be divided into early, ..
  71. Development of a Safer Smallpox Vaccine
    Michael Cho; Fiscal Year: 2003
    ..A successful, worldwide vaccination campaign during the 1950s-l970s, using live vaccinia virus, resulted in eradication of smallpox...
  72. Discovery of antivirals against vaccinia and smallpox
    Robert Ricciardi; Fiscal Year: 2003
    ..To respond to this specific threat, the United States must have at its disposal supplies of both vaccinia virus vaccine and antiviral compounds directed against smallpox infection...
  73. MULTISCALE MODELING TOOLS FOR STRUCTURAL BIOLOGY
    Charles Brooks; Fiscal Year: 2009
    ..poxvirus vaccines against smallpox and other virulent poxviruses, and second, to increase the efficacy of live vaccinia virus vaccines as a vaccine platform for protection against multiple agents important in the fields of biodefense ..
  74. MOLECULAR ENGINEERING OF RETROVIRAL VACCINES
    Edward Stephens; Fiscal Year: 1990
    ..viruses can be utilized as vectors for efficient expression of foreign glycoprotein genes when placed under vaccinia virus transcriptional regulatory signals...